Literature DB >> 2579032

Modulatory effects of 5-azacytidine, phorbol ester, and retinoic acid on the malignant phenotype of human lung cancer cells.

L Olsson, O Behnke, H R Sørensen.   

Abstract

Cloned human cell lines of squamous-cell lung carcinoma and small-cell lung carcinoma were treated with 5-azacytidine (5-azaC), 12-0-tetradecanoyl-phorbol-13 acetate (TPA), retinoic acid (RA), or a combination of these drugs, and the effects on cellular morphology, in vitro growth properties, antigenicity, tumorigenicity and metastatic activity in nude mice were studied. Antigenicity was measured by the expression of major histocompatibility antigens (MHC) and of lung-tumor-associated antigens. 5-AzaC treatment resulted in subclones with shorter population doubling times (from 40-50 hr down to 14-20 hr) and increased cloning efficiencies (from less than 1% to 5-50%). TPA and RA induced loss of proliferative activity in vitro and tumorigenicity in vivo of both lines. This was morphologically associated with the appearance of an abundance of large vaculated cells which by DNA-analysis were all found to be in G0-G1 phase. However, 2 of the 5-azaC-treated subclones were insensitive to both TPA and RA, whereas the remaining subclones (20) all responded like untreated lines to TPA and RA. One of the sublines insensitive to TPA and RA formed metastases in nude mice in contrast to all the other lines used. The density of lung-tumor-associated antigens was significantly reduced by TPA-RA treatment, whereas the expression of MHC antigens was unaffected. In contrast, 5-azaC resulted in some cases in increased density of MHC antigens. The effects of 5-azaC on cellular phenotypes were not directly correlated to the total genomic content of 5-methylcytosine. The data suggest that this experimental system is suitable for studies of phenotypic features of malignant cells as related to cellular differentiation.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2579032     DOI: 10.1002/ijc.2910350209

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  4 in total

1.  Differential growth inhibition and enhancement of major histocompatibility complex class I antigen expression by interferons in a small-cell lung cancer cell line and its doxorubicin-selected multidrug-resistant variant.

Authors:  S P Cole; B M Campigotto; J G Johnson; B E Elliott
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

2.  Induction of invasive and metastatic potential in mouse T-lymphoma cells (BW5147) by treatment with 5-azacytidine.

Authors:  G G Habets; R A van der Kammen; E H Scholtes; J G Collard
Journal:  Clin Exp Metastasis       Date:  1990 Nov-Dec       Impact factor: 5.150

3.  Clonal analysis of the malignant properties of B16 melanoma cells treated with the DNA hypomethylating agent 5-azacytidine.

Authors:  D L Trainer; T Kline; G Hensler; R Greig; G Poste
Journal:  Clin Exp Metastasis       Date:  1988 May-Jun       Impact factor: 5.150

Review 4.  Vitamin A and retinoid derivatives for lung cancer: a systematic review and meta analysis.

Authors:  Heidi Fritz; Deborah Kennedy; Dean Fergusson; Rochelle Fernandes; Steve Doucette; Kieran Cooley; Andrew Seely; Stephen Sagar; Raimond Wong; Dugald Seely
Journal:  PLoS One       Date:  2011-06-27       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.